Tag Archives: Musculoskeletal Disorder Drugs Market Report

High Costs Of Drug Approval Might Slow Down The Pharmaceutical Drugs Market

The pharmaceutical industry develops drugs to diagnose, cure, treat or prevent diseases. Pharmaceutical companies produce both generic and branded drugs. Pharmaceutical drugs are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy and marketing.

Order report at

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-******-market-report-2018

The ****** pharmaceutical drugs market has shown decent growth in the past years with a CAGR of just over 5%. The year 2017 recorded highest ever market value in this industry as per TBRC’s inhouse consultants.

TBRC’s latest report show the historic and future trends in the market for each year with sourced reasons to support the growth claims.

Use Of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) For Acute Musculoskeletal Pain In The ****** Musculoskeletal Drugs Market (Companies Included: F. Hoffmann-La Roche Ltd., GlaxosmithKline Plc, Pfizer Inc., Abbott Laboratories Inc., Daiichi Sankyo Company, Limited)

The musculoskeletal system drugs market comprises companies that discover, develop, manufacture and distribute medications used in the treatment of musculoskeletal diseases. Musculoskeletal diseases include arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus and others. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

Read more:

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorders-drugs-******-market-report-2018

****** Musculoskeletal Drugs Market Is Expected To Grow To $177 Billion By 2021 According To TBRC’s Latest Report

The musculoskeletal system drugs market comprises companies that discover, develop, manufacture and distribute medications used in the treatment of musculoskeletal diseases. Musculoskeletal diseases include arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus and others. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer.

Read the report at

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorders-drugs-******-market-report-2018

The substantial reason for the growth of the musculoskeletal system drugs market from $130 billion in 2017 to $177 billion in 2021. This can be attributed to the expected increase in healthcare awareness, number of surgical operations and prevalence of musculoskeletal disorders such as fibromyalgia, rheumatoid arthritis, osteoarthritis around the world.  Also, increasing number of road accidents and workplace injuries are expected to contribute to market growth.

Drugs To Treat Metabolic Disorders Present The Best Opportunities For Pharma Companies, Says TBRC

The fastest-growing segment of the ****** pharma market to 2021 will be in drugs for treating metabolic disorders such as diabetes and disorders of the thyroid and pituitary gland, a report from The Business Research Company shows. This market will grow at 9% a year going forward, following recent growth of 11.6%, but it will remain in fifth place for market size behind the musculoskeletal, cardiovascular, oncology and anti-infective drug markets. Drugs to treat diabetes account for over 97% of the ****** metabolic pharma market.

 

Brazil, Russia And India Offer The Best Opportunities In The Musculoskeletal Drugs Markets To 2020

Three of the BRICs (Brazil, Russia and India) have high recent and forecast market growth rates for musculoskeletal drugs and so will move up the table of consumer countries for these drugs. Currently the largest markets for drugs that treat diseases such as arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome and muscular dystrophy are in countries such as the USA and Japan and China; the USA’s market is and will remain vastly bigger than any other, but the three BRIC markets are beginning to catch up with Japan and China. For example, while India’s market was only two-thirds of Japan’s in 2016, by 2020 its sales will be equal to 84% of the Japanese sales. Again, Again, Brazil’s market was only half as big as China’s in 2016 but will be worth nearly 60% of that market by 2020.